Novel Melanocortin Receptor Probe Discovery
新型黑皮质素受体探针的发现
基本信息
- 批准号:9077902
- 负责人:
- 金额:$ 37.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:ART proteinAdverse effectsAffectAgonistAmino AcidsAreaBindingBody mass indexBrainCentral Nervous System AgentsClinical TrialsComplexCountryCoupledDataDeveloped CountriesDietDiseaseExerciseFatty acid glycerol estersFigs - dietaryG-Protein-Coupled ReceptorsGTP-Binding ProteinsGenesGeneticGoalsHeart DiseasesHomeostasisHomodimerizationHumanHyperphagiaHypertensionKnowledgeLigandsLinkMalignant NeoplasmsMediatingMelanocortin 3 ReceptorMelanocortin 4 ReceptorModificationMolecularMolecular Mechanisms of ActionMolecular ProbesMorbidity - disease rateMusN-terminalNeurosecretory SystemsNon-Insulin-Dependent Diabetes MellitusObesityOutcomePathway interactionsPharmaceutical ChemistryPro-OpiomelanocortinRegulationReportingResearchResearch Project GrantsRisk FactorsRoleSatiationStrokeTertiary Protein StructureTherapeuticTranscriptUnited StatesWeightbasedesigndrug discoveryfeedingmelanocortin receptornovelpublic health relevancereceptorreceptor bindingtherapeutic developmenttherapeutic targettool
项目摘要
DESCRIPTION (provided by applicant): Obesity afflicts millions of people, and is a major risk factor for Type II diabetes and morbidity. The melanocortin pathway has been clearly identified in mice and humans to be involved in the regulation of satiety, obesity, and energy homeostasis. The goal of this research project is characterize the human melanocortin-4 receptor (MC4R) N- terminal 1-26 domain peptide agonist, identify how it molecularly interacts with the MC4R to mechanistically function as a full agonist. These data will be used to generate novel and potent MC4R agonist molecules as molecular probes and potential central nervous system (CNS) drugs. The impact of the anticipated results on the medicinal chemistry and obesity research fields could challenge the existing paradigms for ligand design strategies for melanocortin receptor based therapeutics, GPCR based therapeutics, as well as provide novel tools to probe weight and energy homeostasis.
描述(由申请人提供):肥胖困扰着数百万人,是II型糖尿病和发病的主要危险因素。在小鼠和人类中,黑皮质素通路已被明确鉴定为参与饱腹感、肥胖和能量稳态的调节。本研究的目的是表征人黑皮质素-4受体(MC 4 R)N-末端1-26结构域肽激动剂,确定其如何与MC 4 R分子相互作用以作为完全激动剂发挥作用。这些数据将用于产生新的和有效的MC 4 R激动剂分子作为分子探针和潜在的中枢神经系统(CNS)药物。预期结果对药物化学和肥胖研究领域的影响可能会挑战现有的基于黑皮质素受体的治疗剂、基于GPCR的治疗剂的配体设计策略的范例,以及提供探测体重和能量稳态的新工具。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carrie Haskell-Luevano其他文献
Carrie Haskell-Luevano的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carrie Haskell-Luevano', 18)}}的其他基金
Chemical biology of Peptide Regulation of Opioid Receptor Function
阿片受体功能肽调节的化学生物学
- 批准号:
10578830 - 财政年份:2020
- 资助金额:
$ 37.21万 - 项目类别:
Chemical biology of Peptide Regulation of Opioid Receptor Function
阿片受体功能肽调节的化学生物学
- 批准号:
10348174 - 财政年份:2020
- 资助金额:
$ 37.21万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 37.21万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 37.21万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 37.21万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 37.21万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 37.21万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 37.21万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 37.21万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 37.21万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 37.21万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 37.21万 - 项目类别:
Studentship














{{item.name}}会员




